European Protected Waveform Consortium Achieves Major Milestone with Successful Over-the-Air Testing
Demonstration underscores Europe's commitment to secure, resilient, multi-orbit military satellite communications SINT-NIKLAAS, Belgium, Dec. 10, 2025 /PRNewswire/ -- ST Engineering iDirect's EU Satcom Centre of Excellence, ST Engineering iDirect...
Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025
SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, announced new data from its hematology portfolio at the 67th American Society of...
Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
- ASC30 once-daily tablets showed statistically significant and clinically meaningful dose-dependent placebo-adjusted mean body weight reductions with no observed plateau for weight loss. - ASC30 titrated weekly to target dose demonstrated...
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo1 Holistic benefit: secondary endpoints showed significant...
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
SAN FRANCISCO and SUZHOU, China, Dec. 8, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of...
TransThera Publishes Clinical Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Lancet
NANJING, China and GAITHERSBURG, Md., Dec. 5, 2025 /PRNewswire/ -- TransThera Sciences Inc. ("TransThera") announced the publication of clinical results from a US-based Phase 2 trial evaluating tinengotinib in patients with Cholangiocarcinoma (CCA)...
High Response in Bladder Cancer: Immvira Announced Its MVR-T3011 Latest Clinical Results in BCG-Unresponsive Bladder Cancer Patients at 2025 Annual Meeting of the Society of Urologic Oncology
SUZHOU, China, Dec. 4, 2025 /PRNewswire/ -- On December 3, 2025 (local time in Arizona, USA), ImmVira Group ("ImmVira" or the "Company") announced a poster presentation at the 26th Annual Meeting of the Society of Urologic Oncology (SUO 2025). The...
Successful Hot Fire Test on a Solid Rocket Motor Thrust Chamber Additively Manufactured by Titomic's TKF™ Cold Spray
HUNTSVILLE, Ala., Dec. 4, 2025 /PRNewswire/ -- Titomic Limited (ASX: TTT), a global leader in cold spray additive manufacturing utilizing their Titomic Kinetic Fusion™ technology, is pleased to announce the successful completion of a hot fire test...
Breaking Boundaries with Light and Shadow, Sailing Forward from Zhejiang: The Splendid Opening of the 2025 Zhejiang Service Trade (Singapore) Film & Television Exhibition
HANGZHOU, China, Dec. 3, 2025 /PRNewswire/ -- A news report from Department of Commerce of Zhejiang Province: On December 3rd, the 2025 Zhejiang Service Trade (Singapore) Film & Television Exhibition, themed "Service of Zhejiang, Serve the...
TCab Tech E20 eVTOL Successfully Completes Transition Flight Tests
SHANGHAI, Dec. 3, 2025 /PRNewswire/ -- TCab Tech announced today that its full-scale E20 eVTOL demonstrator has successfully completed transition flight tests, marking a critical milestone in the program's development. During the flight campaign,...